CARDIOL THERAPEUTICS INC-A (CRDL) Stock Income Statement
NASDAQ:CRDL - Nasdaq - CA14161Y2006 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 80.00K | |||
| Operating Expenses | 40.30M | 40.28M | 29.79M | 41.34M | 38.74M | |||
| Research and Development | 14.45M | 14.01M | 14.22M | 18.96M | 10.87M | |||
| Selling, General, and Administrative Expenses | 25.54M | 25.91M | 15.31M | 22.15M | 27.65M | |||
| Operating Income | -40.30M | -40.28M | -29.79M | -41.34M | -38.66M | |||
| Interest Income/Expense | 4.51M | 3.57M | 1.51M | 10.24M | 6.91M | |||
| Other Income/Expense | 0.00 | 28.20K | 149.70K | 160.00K | 110.00K | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -35.79M | -36.68M | -28.13M | -30.93M | -31.64M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -35.79M | -36.68M | -28.13M | -30.93M | -31.64M | |||
| EBITDA | -39.96M | -39.90M | -29.54M | -41.12M | -38.44M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.48 | -0.51 | -0.44 | -0.49 | -0.73 | |||
| Non GAAP EPS | -0.47 | -0.51 | -0.44 | -0.49 | N/A | |||
| Statistics | ||||||||
| Profit Margin | N/A | N/A | N/A | N/A | -39550.00% | |||
| Operating Profit Margin | N/A | N/A | N/A | N/A | -48325.00% | |||
All data in CAD